title: Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.
abstract: Dyslipidemia and coronary heart disease (CHD) are of increasing concern in persons with human immunodeficiency virus (HIV) infection who are living longer because of the benefits of highly active antiretroviral therapy (HAART). All classes of drugs used in HAART have been associated with atherogenic changes in lipid profiles. The management of HIV-infected persons with dyslipidemia and/or CHD currently emphasizes the importance of monitoring and optimizing lipid levels through lifestyle changes, switching antiretrovirals (ARVs), and lipid-lowering treatments utilizing guidelines developed for persons without HIV infection. In HIV-infected persons, the use of lipid-lowering drugs may result in pharmacokinetic interactions with ARVs, complicating the management of patients. Recent advances in our understanding of the differential effects of specific ARVs on lipids is beginning to alter the clinical approach to management. In the absence of randomized clinical trials, clinicians should aggressively treat atherogenic dyslipidemia by primarily utilizing or switching to ARVs with the lowest potential to induce CHD or, when this is not possible or is ineffective, secondarily by the addition of lipid-lowering therapy. The current optimal management of HIV infection requires careful selection of ARVs with consideration given to the potential development of CHD and an understanding of how to manage dyslipidemia.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0405, USA. Carl.Fichtenbaum@uc.edu
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Fichtenbaum
mesh_terms: D000465:Algorithms; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D003324:Coronary Artery Disease / Q000139:chemically induced / Q000517:prevention & control*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D012307:Risk Factors